Shares

20 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 13, 2024

BUY
$2.58 - $3.23 $4,969 - $6,220
1,926 New
1,926 $5,000
Q3 2023

Nov 09, 2023

BUY
$2.56 - $4.4 $215 - $369
84 New
84 $0
Q1 2023

May 12, 2023

SELL
$1.32 - $1.89 $2,269 - $3,248
-1,719 Reduced 45.75%
2,038 $3,000
Q4 2022

Feb 08, 2023

SELL
$1.13 - $1.62 $3,880 - $5,563
-3,434 Reduced 47.75%
3,757 $5,000
Q3 2022

Nov 10, 2022

BUY
$1.2 - $2.07 $4,993 - $8,613
4,161 Added 137.33%
7,191 $9,000
Q2 2022

Aug 10, 2022

BUY
$1.86 - $2.62 $3,868 - $5,449
2,080 Added 218.95%
3,030 $6,000
Q1 2022

May 16, 2022

SELL
$2.29 - $3.88 $8,399 - $14,231
-3,668 Reduced 79.43%
950 $2,000
Q4 2021

Feb 14, 2022

BUY
$3.43 - $4.65 $15,839 - $21,473
4,618 New
4,618 $17,000
Q3 2021

Nov 15, 2021

SELL
$3.1 - $4.32 $64,216 - $89,488
-20,715 Closed
0 $0
Q2 2021

Aug 13, 2021

BUY
$4.45 - $9.91 $87,509 - $194,880
19,665 Added 1872.86%
20,715 $92,000
Q1 2021

May 12, 2021

BUY
$7.76 - $10.43 $1,055 - $1,418
136 Added 14.88%
1,050 $10,000
Q4 2020

Feb 11, 2021

BUY
$4.13 - $10.14 $3,774 - $9,267
914 New
914 $9,000
Q3 2020

Nov 12, 2020

SELL
$3.91 - $7.15 $2,302 - $4,211
-589 Closed
0 $0
Q2 2020

Jul 31, 2020

SELL
$2.6 - $7.32 $20,568 - $57,908
-7,911 Reduced 93.07%
589 $4,000
Q1 2020

May 01, 2020

BUY
$2.25 - $5.64 $19,125 - $47,940
8,500 New
8,500 $24,000
Q4 2019

Feb 14, 2020

SELL
$1.8 - $5.04 $4,237 - $11,864
-2,354 Closed
0 $0
Q3 2019

Nov 14, 2019

BUY
$2.07 - $4.88 $215 - $507
104 Added 4.62%
2,354 $5,000
Q2 2019

Aug 14, 2019

BUY
$2.7 - $4.96 $6,075 - $11,160
2,250 New
2,250 $11,000
Q1 2019

May 14, 2019

SELL
$3.1 - $4.54 $4,101 - $6,006
-1,323 Closed
0 $0
Q4 2018

Feb 14, 2019

BUY
$2.65 - $9.2 $3,505 - $12,171
1,323 New
1,323 $4,000

Others Institutions Holding DMAC

About DiaMedica Therapeutics Inc.


  • Ticker DMAC
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 26,443,100
  • Market Cap $116M
  • Description
  • DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, develops treatments for neurological and kidney diseases. The company's lead drug candidate is DM199, a recombinant human tissue kallikrein-1 protein, which is in Phase 2 REDUX trial for the treatment of patients with moderate or severe chronic kidney disease caused by Type...
More about DMAC
Track This Portfolio

Track Ubs Group Ag Portfolio

Follow Ubs Group Ag and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Group Ag with notifications on news.